Skip to main content
. 2015 Oct 19;6(37):40005–40025. doi: 10.18632/oncotarget.5552

Figure 5. Expression of stemness markers after CPT treatment of SKOV3 cells.

Figure 5

A. Flow cytometry dot plot and B. histogram of nuclear OCT4 in untreated SKOV3 cells, SKOV3 cells treated for 14 days 21 weeks. The x-axis in panel A shows the forward scatter as an indication of cell size. A validation of the OCT4 antibody is shown in Figure S5. C. Quantitation of the transcriptional activity of OCT4 in SKOV3 cells harboring a stably integrated luciferase reporter construct driven by OCT4 binding sites after different times of CPT treatment. D. RT-qPCR analysis of POU5F1 mRNA levels (sample size: n ≥ 3). E. Median fluorescence intensity (MFI) determined by flow cytometry for stem cell markers (CD24, CD44, CD117 and CD133 surface expression and nuclear OCT4, SOX2 and NANOG) after different times of CPT treatment (sample size: n ≥ 3).